Carisma Therapeutics Inc. (W2J)
XMUN 
Summary
W2J Chart
CARISMA THERAP (CARM) Upgraded to Buy: What Does It Mean for the Stock?
CARISMA THERAP (CARM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Carisma Therapeutics Inc. (CARM) Reports Q2 Loss, Tops Revenue Estimates
Carisma Therapeutics Inc. (CARM) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.49 per share a year ago.
Carisma Therapeutics Inc. (W2J) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Carisma Therapeutics Inc. ever had a stock split?
Carisma Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Saar Gill CEO | XMUN Exchange | US14216R1014 ISIN |
| US Country | 46 Employees | 8 Mar 2023 Last Dividend | 8 Mar 2023 Last Split | - IPO Date |
Overview
Carisma Therapeutics, Inc. is a ground-breaking clinical-stage biotechnology company, primarily engaged in the pursuit of novel immunotherapies aiming to revolutionize the treatment of cancer and other serious diseases within the United States. With its inception in 2016 and originally known as CARMA Therapeutics Inc., the company underwent a name change in May 2017 to better reflect its broadened therapeutic focus and ambitions. Located in Philadelphia, Pennsylvania, Carisma Therapeutics spearheads the development of cutting-edge cell therapies leveraging chimeric antigen receptor (CAR) technology, specifically focusing on macrophages and monocytes to target and combat malignancies and diseases with high unmet medical needs.
Products and Services
- CT-0508 (CAR-macrophage)
A pioneering cell therapy, CT-0508 incorporates CAR-engineered macrophages designed to fight solid tumors. Currently, this innovative approach is being evaluated in a Phase 1 clinical trial, representing a significant step towards harnessing the potential of macrophages in cancer treatment.
- CT-0525 (CAR-monocyte)
Another novel cell therapy in the company's portfolio is CT-0525, which utilizes CAR-engineered monocytes for the treatment of solid tumors. This therapeutic candidate is undergoing Phase 1 clinical trials, indicating its progress in the journey from concept to potential cancer treatment.
- CT-1119 (Mesothelin-targeted CAR-Monocyte)
At the pre-clinical development stage, CT-1119 focuses on advanced mesothelin-positive solid tumors, including aggressive forms like lung cancer, mesothelioma, pancreatic cancer, and ovarian cancer. By targeting mesothelin, a protein frequently overexpressed in several types of cancer, CT-1119 represents a tailored approach to fight specific malignant diseases.
- In Vivo CAR-M Cell Therapies
In partnership with Moderna Therapeutics, Carisma is expanding its innovative treatment paradigm to develop in vivo CAR-M cell therapies. Targeting multiple cancer entities, this collaboration emphasizes the company's dedication to leveraging leading-edge technology for cancer treatment—not just ex vivo, but also through direct in vivo applications.
- Assets Beyond Oncology
Expanding its horizon beyond cancer treatment, Carisma Therapeutics is actively exploring the potential of its cell therapy technology to address diseases in other therapeutic areas. This includes research and development efforts aiming at the treatment of fibrosis as well as various immunologic and inflammatory diseases, showcasing the versatility and potential impact of CAR-M based therapies across a broader spectrum of conditions.
Contact Information
